These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15297407)

  • 21. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
    Ebbinghaus S; Rubin E; Hersh E; Cranmer LD; Bonate PL; Fram RJ; Jekunen A; Weitman S; Hammond LA
    Clin Cancer Res; 2005 Nov; 11(21):7807-16. PubMed ID: 16278403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
    Soepenberg O; de Jonge MJ; Sparreboom A; de Bruin P; Eskens FA; de Heus G; Wanders J; Cheverton P; Ducharme MP; Verweij J
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):703-11. PubMed ID: 15701859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.
    Eder JP; Supko JG; Lynch T; Bryant M; Vosburgh E; Shulman LN; Xu G; Kufe DW
    Clin Cancer Res; 1998 Feb; 4(2):317-24. PubMed ID: 9516917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
    Erlichman C; Hidalgo M; Boni JP; Martins P; Quinn SE; Zacharchuk C; Amorusi P; Adjei AA; Rowinsky EK
    J Clin Oncol; 2006 May; 24(15):2252-60. PubMed ID: 16710023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks.
    Minami H; Fujii H; Igarashi T; Itoh K; Tamanoi K; Oguma T; Sasaki Y
    Clin Cancer Res; 2001 Oct; 7(10):3056-64. PubMed ID: 11595695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas.
    Tedesco KL; Berlin J; Rothenberg M; Choy H; Wyman K; Scott Pearson A; Daniel Beauchamp R; Merchant N; Lockhart AC; Shyr Y; Caillouette C; Chakravarthy B
    Radiother Oncol; 2005 Jul; 76(1):54-8. PubMed ID: 15921772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
    Ricart AD; Sarantopoulos J; Calvo E; Chu QS; Greene D; Nathan FE; Petrone ME; Tolcher AW; Papadopoulos KP
    Clin Cancer Res; 2009 Jun; 15(11):3866-71. PubMed ID: 19458055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva.
    de Jonge MJ; Verweij J; Loos WJ; Dallaire BK; Sparreboom A
    Clin Pharmacol Ther; 1999 May; 65(5):491-9. PubMed ID: 10340914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
    Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
    Giles FJ; Cortes JE; Thomas DA; Garcia-Manero G; Faderl S; Jeha S; De Jager RL; Kantarjian HM
    Clin Cancer Res; 2002 Jul; 8(7):2134-41. PubMed ID: 12114413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
    Cunningham C; Appleman LJ; Kirvan-Visovatti M; Ryan DP; Regan E; Vukelja S; Bonate PL; Ruvuna F; Fram RJ; Jekunen A; Weitman S; Hammond LA; Eder JP
    Clin Cancer Res; 2005 Nov; 11(21):7825-33. PubMed ID: 16278405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
    Hidalgo M; Buckner JC; Erlichman C; Pollack MS; Boni JP; Dukart G; Marshall B; Speicher L; Moore L; Rowinsky EK
    Clin Cancer Res; 2006 Oct; 12(19):5755-63. PubMed ID: 17020981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas.
    Patel SR; Beach J; Papadopoulos N; Burgess MA; Trent J; Jenkins J; Benjamin RS
    Cancer; 2003 Jun; 97(11):2848-52. PubMed ID: 12767099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study.
    Chatterjee A; Digumarti R; Katneni K; Upreti VV; Mamidi RN; Mullangi R; Surath A; Srinivas ML; Uppalapati S; Jiwatani S; Srinivas NR
    J Clin Pharmacol; 2005 Apr; 45(4):453-60. PubMed ID: 15778426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
    Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation study.
    Chatterjee A; Digumarti R; Mamidi RN; Katneni K; Upreti VV; Surath A; Srinivas ML; Uppalapati S; Jiwatani S; Subramaniam S; Srinivas NR
    J Clin Pharmacol; 2004 Jul; 44(7):723-36. PubMed ID: 15199077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
    Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
    Rubin EH; Rothermel J; Tesfaye F; Chen T; Hubert M; Ho YY; Hsu CH; Oza AM
    J Clin Oncol; 2005 Dec; 23(36):9120-9. PubMed ID: 16301595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.